FDA Finalizes Rule for Additional Conditions for Nonprescription Drugs (ACNU)
Transition from Proposal to Final Rule
The U.S. Food and Drug Administration (FDA) finalized its rule for Additional Conditions for Nonprescription Use (ACNU) on December 26, 2024, after proposing it in June 2022. The effective date was twice delayed due to the President's regulatory freeze review and is now May 27, 2025. This is not a scheduled action but a regulatory milestone achieved. The rule allows for nonprescription access to drugs for which adequate labeling alone cannot ensure safe self-selection and actual use by combining FDA-approved conditions, such as questionnaires or electronic confirmation procedures. A key aspect is the potential to expand the range of candidates for over-the-counter (OTC) distribution to include treatments for chronic conditions.
Approval Thresholds Remain Unchanged
ACNU products must still meet the same safety and efficacy standards as other new drugs and require approval of a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA). Companies seeking to switch already approved prescription drugs must submit a separate nonprescription application, rather than a simple modification of the existing approval. They are also subject to front-of-label warnings, Drug Facts labeling, and post-market reporting requirements for condition failures. Therefore, the rule is not a mechanism to bypass clinical development but rather a pathway to incorporate consumer behavior data, label comprehension studies, and digital interface validation into the commercialization package. The FDA's economic analysis estimates that the reduction in healthcare visits and transportation burden will result in a cost savings of USD 33.62 per consumer per purchase.
Existing OTC Switch Products Serve as Competitive Benchmarks
Currently, there are no FDA-approved ACNU products, so the clinical and commercial leaders in this pathway have yet to emerge. The benchmarks are Narcan (naloxone hydrochloride, a non-selective opioid receptor antagonist), which received nonprescription approval on March 29, 2023, and Opill (norethindrone, a progestin receptor agonist), which was approved on July 13, 2023. Both products are in the approved and marketed stages. Emergent BioSolutions' Narcan is the standard emergency treatment for opioid overdose, and the FDA Advisory Committee unanimously recommended its nonprescription switch. Perrigo's Opill is the first nonprescription daily oral contraceptive in the United States. These are examples of existing Rx-to-OTC switches that have demonstrated self-selection and use through labeling alone; therefore, ACNU candidates must clearly demonstrate the safety improvements provided by the additional procedures.
Market Expansion and Implementation Risks Coexist
The U.S. OTC drug retail market is USD 44.3 billion in 2024, according to CHPA data, and ACNU provides an institutional framework for incorporating complex chronic disease prescriptions into this market. However, if questionnaires or electronic gates reduce purchase conversion rates or exclude patients with limited digital access, prescription barriers may be replaced by technological barriers. For applicant companies, reduced insurance claims and increased direct consumer payments represent revenue opportunities, while separate approval, labeling, and post-market surveillance costs may put pressure on initial profitability. The indication, condition failure rate, and retail distribution design of the first approved product will determine the regulatory precedent and valuation criteria for subsequent ACNU pipelines.
From an investor's perspective, ACNU represents a new lifecycle management pathway for connecting chronic disease prescriptions to the USD 44.3 billion U.S. OTC market in 2024, but the absence of currently approved products means that the first applicant faces significant implementation risk. Researchers must design self-selection questionnaires, actual use, and condition failure data in addition to the label-based switch studies of Narcan and Opill, which are in the approved and marketed stages. In the existing OTC switch market, where Emergent BioSolutions and Perrigo have a head start, differentiation is required to demonstrate that the additional digital procedures simultaneously improve access and safety. In the short term, separate NDA/ANDA and post-market reporting costs may be burdensome, but in the medium to long term, the consumer access cost savings of USD 33.62 per purchase and the reduction in insurance claims will support adoption. The first ACNU approval and condition failure rate will be key catalysts that will directly impact the approval probability, retail distribution, and corporate valuation of subsequent pipelines.